|Articles|January 3, 2019

GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to a Diagnostic Assay for Non-Alcoholic SteatoHepatitis

LabCorp, a global life sciences company, and GENFIT, a late-stage biopharmaceutical company, have announced the signing of a licensing agreement between GENFIT and Covance, LabCorp’s drug development business. The agreement hopes to expand access to an innovative non-alcoholic steatohepatitis (NASH) liver diagnostic test for the clinical research market.

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

ByMarcela Roy, MA, Lauren Crooks, MSc, Graham Ellis, MD, Alan Kott, MUDR, Dawie Wessels, MD, Elias Ketiar, MD, MRCP

June 4th 2026

For pharmaceutical and life sciences organizations, the strategic imperative is clear: begin immediately with foundation building, scale systematically with measurable milestones, and transform comprehensively toward AI-native data operations. Credit: Stock.Adobe.com/tippapatt.

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

ByPartha Anbil,Partha Khot

June 4th 2026

GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to a Diagnostic Assay for Non-Alcoholic SteatoHepatitis

Related Content

A Shot in the Arm to Traditional Vaccine Trial Strategy

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

ACT Brief: Site-First Technology Strategy, AI Data Harmonization Architecture, and Obesity Trial Retention

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

Trending on Applied Clinical Trials Online

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

A Shot in the Arm to Traditional Vaccine Trial Strategy

SCOPE X: The COPD Case Study That Shows What AI Can Do for Enrollment